Crohn’s Disease - Canada Drug Forecast and Market Analysis to 2022, New Report Launched

The Crohn’s disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge the current biologics in an attempt to dislodge the stronghold of the TNF inhibitors, as they aim to tap into the lucrative portion of the CD therapeutics market. If their promising safety and efficacy profiles translate to clinical practice once they enter the market, their launch will be to the detriment of the existing market leaders, Remicade (infliximab) and Humira (adalimumab).The loss of patent protection of the anti-TNF marketed brands will allow for the emergence of biosimilars, such as Hospira’s Inflectra (infliximab) a Remicade biosimilar. Focusing on country dynamics, Canada and the emerging markets of China and India will also play a key role in driving growth in the long term, with each market forecast to post positive Compound Annual Growth Rates (CAGRs) from 2012 to 2022, primarily due to the anticipated strong uptake of Remicade over the forecast period.

Based on Publisher’s primary research survey, the majority of Canadian gastroenterologists follow the AGA guidelines for the management of their CD patients. Over 65% of referrals for CD patients to a gastroenterologist come from PCPs or colorectal surgeons. The peak age for the diagnosis of CD in over 65% of cases in Canada is 17–40 years, and the diagnosis is typically confirmed by clinical evaluation and a combination of hematological, endoscopic, histological, or imaging-based investigations following the initial presenting symptoms of abdominal pain, diarrhea, and weight loss, or the more common systemic symptoms of malaise, anorexia, and fever.

Scope

• Overview of Crohn’s disease including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on the key drugs in Canada including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for the top drugs in Canada from 2012-2022.
• Analysis of the impact of key events as well the drivers and restraints affecting the Canada Crohn’s disease market.

Reasons to buy

• Understand and capitalize by identifying products that are most likely to ensure a robust return.
• Stay ahead of the competition by understanding the changing competitive landscape for Crohn’s disease..
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
• Make more informed business decisions from insightful and in-depth analysis of drug performance.
• Obtain sales forecast for drugs from 2012-2022 in Canada.

Spanning Over 128 pages, 37 tables, 5 figures, “Crohn’s Disease - Canada Drug Forecast and Market Analysis to 2022” report covering the Disease Overview, Disease Management, Competitive Assessment, Opportunity and Unmet Need, Pipeline Assessment, Market Outlook, Canada, Appendix.

See more at: http://mrr.cm/Z3s

For regular industry updates subscribe to our newsletter at: 

http://www.marketresearchreports.com/subscribe-to-newsletter